Literature DB >> 10715502

Changes in disclosure of information to cancer patients in a general hospital in Japan.

N Horikawa1, T Yamazaki, M Sagawa, T Nagata.   

Abstract

The disclosure of information to cancer patients is one of the most important issues in oncological practice. In Japan, as in some other countries, few cancer patients were ever given a truthful statement of their diagnosis. However, today more and more patients are being informed of their diagnosis and prognosis. This study investigates the nature of these changes in disclosure policy and suggests possible explanations. We reviewed the medical and nursing charts of 122 adult cancer patients admitted to our hospital in 1993 and 137 admitted in 1998. We examined the information they had been given, and their sociodemographic and medical characteristics. The diagnosis of cancer was shared with 27% of patients in 1993. In 1998, however, 71% were informed of their cancer, and 10% were also told they had a poor prognosis. The rate of disclosure was lower for older patients and those with advanced cancer in both 1993 and 1998. In 1998 the rate was higher in patients undergoing chemotherapy and/or surgery. The higher level of disclosure in 1998 was due basically to the growing importance of informed consent. Psychiatric referrals increased from 2% in 1993 to 10% in 1998. Psychiatrists may have contributed to these changes in the disclosure of information.

Entities:  

Keywords:  Empirical Approach; Professional Patient Relationship

Mesh:

Year:  2000        PMID: 10715502     DOI: 10.1016/s0163-8343(99)00042-0

Source DB:  PubMed          Journal:  Gen Hosp Psychiatry        ISSN: 0163-8343            Impact factor:   3.238


  18 in total

Review 1.  Reluctance to disclose difficult diagnoses: a narrative review comparing communication by psychiatrists and oncologists.

Authors:  Alex J Mitchell
Journal:  Support Care Cancer       Date:  2007-07       Impact factor: 3.603

2.  Construct validity of the EORTC quality of life questionnaire information module.

Authors:  Susanne Singer; Philipp M Engelberg; Gregor Weißflog; Susanne Kuhnt; Jochen Ernst
Journal:  Qual Life Res       Date:  2012-01-17       Impact factor: 4.147

3.  A survey of disclosure of diagnosis to patients with glioma in Japan.

Authors:  Fukuko Yamamoto; Naoya Hashimoto; Naoki Kagawa; Yoshiko Okita; Yasuyoshi Chiba; Noriyuki Kijima; Manabu Kinoshita; Kikuko Yoshizu; Yasunori Fujimoto; Kei Hirai; Toshiki Yoshimine
Journal:  Int J Clin Oncol       Date:  2010-12-08       Impact factor: 3.402

4.  Informed consent in the Pakistani milieu: the physician's perspective.

Authors:  A M Jafarey; A Farooqui
Journal:  J Med Ethics       Date:  2005-02       Impact factor: 2.903

5.  Should cancer patients be informed about their diagnosis and prognosis? Future doctors and lawyers differ.

Authors:  Bernice S Elger; T W Harding
Journal:  J Med Ethics       Date:  2002-08       Impact factor: 2.903

6.  Disclosure preferences regarding cancer diagnosis and prognosis: to tell or not to tell?

Authors:  H Miyata; M Takahashi; T Saito; H Tachimori; I Kai
Journal:  J Med Ethics       Date:  2005-08       Impact factor: 2.903

7.  Evaluation of end of life care in cancer patients at a teaching hospital in Japan.

Authors:  Y Tokuda; N Nakazato; K Tamaki
Journal:  J Med Ethics       Date:  2004-06       Impact factor: 2.903

8.  Information for patients with early-stage prostate cancer: a comparison of professionals' attitudes in Canada and Italy.

Authors:  D Feldman-Stewart; C Capirci; M D Brundage
Journal:  Support Care Cancer       Date:  2003-04-10       Impact factor: 3.603

9.  Non-disclosure of cancer diagnosis: an examination of personal, medical, and psychosocial factors.

Authors:  Csaba L Dégi
Journal:  Support Care Cancer       Date:  2009-01-13       Impact factor: 3.603

10.  Overall information needs of early-stage prostate cancer patients over a decade: highly variable and remarkably stable.

Authors:  Deb Feldman-Stewart; Sarah Brennenstuhl; Michael D Brundage; D Robert Siemens
Journal:  Support Care Cancer       Date:  2008-10-02       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.